Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy

被引:10
|
作者
Onal, Cem [1 ]
Ozyigit, Gokhan [2 ]
Oymak, Ezgi [3 ]
Guler, Ozan Cem [1 ]
Hurmuz, Pervin [2 ]
Tilki, Burak [2 ]
Reyhan, Mehmet [4 ]
Tuncel, Murat [5 ]
Akyol, Fadil [2 ]
机构
[1] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, TR-01120 Adana, Turkey
[2] Hacettepe Univ, Fac Med, Dept Radiat Oncol, Ankara, Turkey
[3] Iskenderun Gelisim Hosp, Div Radiat Oncol, Iskenderun, Hatay, Turkey
[4] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Nucl Med, Adana, Turkey
[5] Hacettepe Univ, Fac Med, Dept Nucl Med, Ankara, Turkey
关键词
lymph node metastasis; nomogram; prostate cancer; prostate‐ specific membrane antigen; staging; RISK; ADENOCARCINOMA; DIAGNOSIS; ANTIGEN; FORMULA; MEN;
D O I
10.1002/pros.24142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Defining the extent of disease spread with imaging modalities is crucial for therapeutic decision-making and definition of treatment. This study aimed to investigate whether clinical parameters and nomograms predict prostate-specific membrane antigen (PSMA)-positive lymph nodes in treatment-naive nonmetastatic prostate cancer (PC) patients. Materials and Methods The clinical data of 443 PC patients (83.3% high-risk and 16.7% intermediate-risk) were retrospectively analyzed. Receiver operating characteristic (ROC) curves with areas under the curve (AUC) were generated to evaluate the accuracy of clinical parameters (prostate-specific antigen [PSA], T stage, Gleason score [GS], International Society of Urological Pathology [ISUP] grade) and nomograms (Roach formula [RF], Yale formula [YF], and a new formula [NF]) in predicting lymph node metastasis. The AUCs of the various parameters and clinical nomograms were compared using ROC and precision-recall (PR) curves. Results A total of 288 lymph node metastases were identified in 121 patients (27.3%) using Ga-68-PSMA-11-positron emission tomography (PET)/computed tomography (CT). Most PSMA-avid lymph node metastases occurred in external or internal iliac lymph nodes (142; 49.3%). Clinical T stage, PSA, GS, and ISUP grade were significantly associated with PSMA-positive lymph nodes according to univariate logistic regression analysis. The PSMA-positive lymph nodes were more frequently detected in patients with PSA >20 ng/ml, GS >= 7 or high risk disease compared to their counterparts. The clinical T stage, serum PSA level, GS, and ISUP grade showed similar accuracy in predicting PSMA-positive metastasis, with AUC values ranging from 0.675 to 0.704. The median risks for PSMA-positive lymph nodes according to the RF, YF, and NF were 31.3% (range: 12.3%-100%), 22.3% (range: 4.7%-100%), and 40.5% (range: 12.3%-100%), respectively. The AUC values generated from ROC and PR curve analyses were similar for all clinical nomograms, although the RF and YF had higher accuracy compared to NF. Conclusion The clinical T stage, PSA, GS, and ISUP grade are independent predictors of PSMA-positive lymph nodes. The RF and YF can be used to identify patients who can benefit from Ga-68-PSMA-11 PET/CT for the detection of lymph node metastasis. Together with nomograms, Ga-68-PSMA-11 PET/CT images help to localize PSMA-positive lymph node metastases and can thus assist in surgery and radiotherapy planning.
引用
收藏
页码:648 / 656
页数:9
相关论文
共 50 条
  • [1] Epididymal Metastasis of Prostate Cancer Detected With 68Ga-PSMA-PET/CT
    Serfling, Sebastian
    Luther, Achim
    Kosmala, Aleksander
    Bluemel, Christina
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (10) : 792 - 793
  • [2] Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients
    Onal, Cem
    Torun, Nese
    Akyol, Fadil
    Guler, Ozan Cem
    Hurmuz, Pervin
    Yildirim, Berna Akkus
    Caglar, Meltem
    Reyhan, Mehmet
    Ozyigit, Gokhan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : E510 - E516
  • [3] 68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer
    Hruby, George
    Eade, Thomas
    Emmett, Louise
    Ho, Bao
    Hsiao, Ed
    Schembri, Geoff
    Guo, Linxin
    Kwong, Carolyn
    Hunter, Julia
    Byrne, Keelan
    Kneebone, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (04) : 343 - 346
  • [4] Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy
    Onal, Cem
    Torun, Nese
    Oymak, Ezgi
    Guler, Ozan C.
    Reyhan, Mehmet
    Yapar, Ali F.
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (06) : 388 - 396
  • [5] Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients
    Onal, Cem
    Ozyigit, Gokhan
    Oymak, Ezgi
    Guler, Ozan Cem
    Tilki, Burak
    Hurmuz, Pervin
    Akyol, Fadil
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (11) : 3683 - 3692
  • [6] Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients
    Cem Onal
    Gokhan Ozyigit
    Ezgi Oymak
    Ozan Cem Guler
    Burak Tilki
    Pervin Hurmuz
    Fadil Akyol
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 3683 - 3692
  • [7] Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
    Dewes, Sabrina
    Schiller, Kilian
    Sauter, Katharina
    Eiber, Matthias
    Maurer, Tobias
    Schwaiger, Markus
    Gschwend, Juergen E.
    Combs, Stephanie E.
    Habl, Gregor
    RADIATION ONCOLOGY, 2016, 11
  • [8] Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer
    Onal, Cem
    Guler, Ozan C.
    Torun, Nese
    Elmali, Aysenur
    Sutera, Philip
    Deek, Matthew P.
    Reyhan, Mehmet
    Yavuz, Melek
    Tran, Phuoc T.
    PROSTATE, 2024, 84 (15) : 1366 - 1374
  • [9] Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer
    Madendere, Serdar
    Kilic, Mert
    Koseoglu, Ersin
    Aykanat, Ibrahim Can
    Eden, Arzu Baygul
    Coskun, Bilgen
    Tekkalan, Fadimana Bozkurt
    Balbay, Mevlana Derya
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (02) : 29.e9 - 29.e15
  • [10] Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
    Leitsmann, Conrad
    Schmid, Marianne
    Sahlmann, Carsten-Oliver
    Trojan, Lutz
    Strauss, Arne
    FRONTIERS IN SURGERY, 2021, 8